Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study

PUP-SWITCH, a study focusing on PUPs undergoing a product class switch from pdFVIII to rFVIII after 50 EDs, showed that switching appears to be safe pertaining to the risk of development of new inhibitors.

Authors

Institutions

Publication Details

Journal
Research and Practice in Thrombosis and Haemostasis
Published
2024-10-18
DOI
https://doi.org/10.1016/j.rpth.2024.102595
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study

Barış Yılmaz, Amin Shahsavani, Sinan Akbayram, Canan Albayrak et al.
Research and Practice in Thrombosis and Haemostasis
Hemophilia Treatment and Research
article

Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study

Barış Yılmaz, Amin Shahsavani, Sinan Akbayram, Canan Albayrak, Mohsen Saleh Elalfy, Frits R. Rosendaal, Behnaz Habibpanah, Susan Halimeh, Gabriella Nicolò, Zühre Kaya, Mehran Karimi, Nazan Sarper, Flora Peyvandi, Yılmaz Ay, Dilek Gürlek Gökçebay, Syna Miri, Sara Scardo, Ahmad Mohammadi, Kaan Kavaklı, Peyman Eshghi, Tiraje Çelkan, Namık Yaşar Özbek, Soha Mohammadi Moghaddam, Pier Mannuccio Mannucci, Burçak Tatlı Güneş
article en

Abstract

PUP-SWITCH, a study focusing on PUPs undergoing a product class switch from pdFVIII to rFVIII after 50 EDs, showed that switching appears to be safe pertaining to the risk of development of new inhibitors.

Research and Practice in Thrombosis and HaemostasisVol. 8(8)
Ain Shams University (EG), American University in Dubai (AE), University of Milan (IT), Shiraz University of Medical Sciences (IR), Ondokuz Mayıs University (TR), Leiden University Medical Center (NL), Dubai Hospital (AE), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Hemophilia Center of Iran (IR), Memorial Ankara Hospital (TR), Istanbul University-Cerrahpaşa (TR), Rhine-Ruhr Institute for Applied Systeminnovation (DE), Hemophilia Center of Western Pennsylvania (US), Izmir Tepecik Eğitim ve Araştırma Hastanesi (TR), American College of Dubai (AE), Pamukkale University (TR), Kocaeli Üniversitesi (TR), Shahid Beheshti University of Medical Sciences (IR), Gaziantep University (TR), Istanbul University (TR), Marmara University (TR), Gazi University (TR)
European Commission, Ministero della Salute, Agenzia Italiana del Farmaco, Ministero della Salute
Openalex Percentile: Top 71%
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.